Synektik Spółka Akcyjna (GPW: SNT)

Deep Dive Research Report

Sector: Healthcare / Medical Technology Distribution and Radiopharmaceuticals Listing: Warsaw Stock Exchange (Główny Rynek GPW), ticker SNT Fiscal year: 1 October to 30 September Report date: 25 September 2026

A note on reporting periods and source material

Synektik's fiscal year runs from 1 October to 30 September, and the company labels each year by its starting calendar year (so "FY2025" means October 2025 to September 2026). The company reports quarterly, including a standalone Q4 report ahead of the full annual report.

Working forward from that calendar: the most recent completed and released period is Q3 FY2025/26 (April to June 2026), published on 5 August 2026 (Synektik financial reports page). The fiscal year ends five days from this report's date, so Q4 and the full-year FY2025/26 figures are not yet due; historically Synektik releases preliminary revenue estimates in late October and the full annual report in mid-December (the FY2024/25 annual report was published 19 December 2025).

Synektik does not hold US-style earnings calls with transcripts. The equivalent, and what this report uses, is the dated management commentary that accompanies each periodic report: the PAP Biznes and press briefings given by the Management Board on results day, the company's own results press releases, and the periodic investor chats hosted on the Strefa Inwestorów platform. Six such reporting events are used throughout, listed in Section 9.

1. What the company does

Synektik sells expensive, complicated medical machines to hospitals, installs them, trains the staff who use them, and then spends the next decade servicing those machines and selling the disposable parts they consume. Separately, it manufactures short-lived radioactive tracers that are injected into patients before a PET-CT scan, and it writes software that stores and moves hospital imaging data.

Put more precisely: Synektik is the exclusive regional distributor and lifecycle service partner for several of the world's most advanced surgical and therapeutic platforms across Poland, the Czech Republic, Slovakia, Lithuania, Latvia, Estonia and now Ukraine. Its anchor relationship is with Intuitive Surgical, whose da Vinci robotic surgery systems Synektik has distributed in Poland since 2018 and across the wider region since. It is also the manufacturer of PET-CT radiopharmaceuticals through its subsidiary Synektik Pharma, operating three production sites in Poland.

Founding and evolution

The company was established in October 2001 as Synektik Sp. z o.o. Per the company's own history page, registration in the National Court Register followed in 2002, together with the creation of its assembly and service departments and a partnership agreement with Siemens (Synektik Group History).

Cezary Kozanecki is the founder and has been President of the Management Board continuously since the company's establishment in October 2001, and President of Synektik SA since 11 January 2011. He graduated in veterinary medicine from the Warsaw University of Life Sciences (then the Agricultural Academy in Warsaw) in 1986 (Biznes PAP, report 63/2024). Dariusz Korecki has been Vice President of the Management Board since 2011; Polish business press describes him as the board member responsible for finance. Both were reappointed for a further three-year term by the Supervisory Board in 2024. Prior employment history for either man beyond these roles is not disclosed in the sources reviewed for this report, and is therefore not stated here.

The business has been rebuilt twice. The first version, roughly 2001 to 2010, was a service-and-assembly house for imported imaging equipment, with an accredited testing laboratory added in 2004 and 2006 and an IT department for medical data archiving created in 2003. The second version began in 2010, when Synektik acquired 100% of IASON Sp. z o.o. and licensed radiopharmaceutical production technology; a manufacturing permit followed in 2011, the same year the company converted to a joint-stock company and listed on NewConnect. It moved to the main GPW market in 2014 and opened a Research and Development Centre the same year.

The third and decisive version began in 2018, on two fronts. Synektik merged Synektik Pharma and Iason into a single radiopharmaceutical entity, and it became the exclusive distributor of da Vinci robotic surgery systems in Poland. That second decision is the one that explains almost everything about the company today.

The core value proposition

Central and Eastern European hospitals are overwhelmingly public, buy through open public tenders, and have very little in-house capability to select, commission, validate, staff-train and maintain a machine that costs eight figures in Polish zloty and has to run safely for a decade. They also cannot buy such machines out of operating cash; they buy them when a specific pot of capital appears, usually EU structural funds, the National Recovery Plan (KPO), the Medical Fund, or a regional government budget.

Synektik's proposition to the hospital is that it takes the entire problem. It writes the tender response, delivers and installs, trains the surgical and technical teams, holds the regulatory and certification burden, and then contracts to supply consumables and service for nine or ten years. Its proposition to the manufacturer, whether that is Intuitive Surgical in California or HistoSonics in Minnesota, is that it already has the tender machinery, the service engineers, the regulatory files and the hospital relationships across seven countries that no foreign manufacturer would want to build from scratch for a market this size.

The technical nature of what is hard here

Three things are genuinely difficult to replicate.

First, the service and consumable infrastructure. A da Vinci system in a district hospital in Włocławek or Bielsko-Biała needs a field engineer who can be there quickly, spare parts held locally, and a supply chain for surgical instruments that are themselves sterile, life-limited and individually tracked. Building that across seven countries takes years and a large fixed cost base that only pays back over a large installed fleet. Synektik entered Q2 FY2025/26 servicing 132 active da Vinci systems in the region, up from 122 three months earlier (SII analysis of Q2 FY2025/26).

Second, the radiopharmaceutical physics. Fluorine-18, the isotope in the most widely used PET tracer, has a half-life of about 110 minutes. A batch made at eight in the morning is largely gone by lunchtime. This means the product cannot be imported, cannot be stockpiled, and must be produced in a cyclotron within a few hours' drive of the scanner that will use it. Production must run to GMP pharmaceutical standards. The result is a business with the economics of a local utility rather than a national pharmaceutical market: whoever has a licensed cyclotron near a cluster of PET scanners effectively owns that catchment.

Third, the tender and regulatory competence. Every one of Synektik's large contracts is won through a public procurement procedure under Polish, Czech, Slovak, Estonian or Lithuanian law. The Estonian da Vinci contract signed in September 2026, for example, was concluded by the SYNEKTIK Baltic subsidiary "as part of a public procurement procedure conducted in accordance with Estonian law" (Synektik, 17 September 2026). Getting these right, in seven legal systems, with medical device registration files that must be valid in each, is grinding administrative work that is a real barrier.

What a customer transaction actually looks like

Take the contract Synektik signed with University Clinical Hospital No. 2 of the Medical University in Łódź. The hospital ran an open tender for a da Vinci system. Synektik bid and won. The contract covers delivery of the robot with its equipment, plus successive supplies of surgical tools and consumables over 36 months, for a maximum net value of PLN 27.5 million.

The structure matters. The robot itself is perhaps half to two thirds of that number as a one-time capital sale recognised on installation. The remainder is a multi-year annuity: every robotic prostatectomy consumes a set of instruments with a fixed number of permitted uses, and each of those is an invoice. The hospital cannot buy those instruments from anybody else, because they are proprietary to the platform and Synektik holds the exclusive distribution right in Poland.

Other recent Polish examples show the same shape at different sizes: Wojewódzki Szpital Specjalistyczny in Lublin at PLN 20.8 million net, University Clinical Hospital No. 2 PUM in Szczecin at PLN 18.5 million net, Szpital Wojewódzki in Bielsko-Biała at PLN 12.3 million net in October 2025, and a system for the hospital in Włocławek at around PLN 13 million.

The Estonian deal makes the annuity explicit. The Tallinn hospital contract is worth EUR 9.4 million net, and it includes nine years of service and ten years of consumables supply (Synektik, 17 September 2026). That is not a machine sale. It is a decade-long supply relationship with a machine attached to the front of it.

"The transition from a one-time equipment sales model to one where value is generated over time, with each procedure, each study and each radiopharmaceutical delivery contributing to a repeating revenue stream."

• XTB market analysis of Synektik's business model (XTB, Polska Spółka Miesiąca)

That shift is measurable. Recurring revenue (service, instruments and accessories) reached PLN 347 million in FY2024/25, or 51% of group revenue, against roughly 31% in 2022. By Q3 FY2025/26 it was running at around PLN 390 to 400 million on a trailing twelve-month basis.

2. Business segments

Synektik reports two segments. The first is overwhelmingly dominant and contains several genuinely different businesses, so it is treated below in sub-parts.

2.1 Medical equipment, IT solutions and services

Share of revenue: PLN 692.5 million of PLN 733.4 million in the first nine months of FY2025/26, or roughly 94% (Parkiet, 6 August 2026).

What it does. This segment buys advanced medical hardware from Western manufacturers, wins public tenders for it in seven countries, installs it, trains the clinical teams, and then services it and supplies its consumables for the rest of its operating life. It also now contains a proprietary medical software business.

Within it sit four distinct activities:

(a) Surgical and therapeutic robotics. The anchor is the da Vinci platform from Intuitive Surgical, for which Synektik holds exclusive distribution in Poland (since 2018), the Czech Republic and Slovakia (since 2022), Lithuania, Latvia and Estonia (since 2024) and Ukraine (added February 2026). The agreement runs to the end of 2031 (Synektik, February 2026). Alongside it are the Symani micro- and super-microsurgical robot from Medical Microinstruments, for operating on blood vessels, nerves and lymphatic vessels; the ZAP-X robotic radiosurgery platform for brain lesions; the Exablate Neuro MR-guided focused ultrasound system from Insightec, used to treat essential tremor without opening the skull; and from July 2026 the Edison histotripsy system from HistoSonics.

(b) Imaging and general hospital equipment. The historic base of the company, including diagnostic imaging systems and nuclear medicine equipment, with partners including Hologic and Philips. This is the lower-margin, higher-competition part of the segment.

(c) Hospital pharmacy automation. Robotic systems for hospital pharmacies under the APOTECA and BD Rowa brands, including APOTECA chemo for the automated compounding of chemotherapy drugs, plus electronic pharmacy dispensing cabinets (Irmatic). This is a genuinely separate buying decision inside the hospital, made by the pharmacy rather than the surgical department.

(d) IT solutions. The ArPACS family for medical image archiving and transmission, the Zbadani.pl telemedicine platform for digital diagnostic workflows, SynDose for patient radiation dose monitoring, and MedDream Viewer. This was materially enlarged by the January 2025 acquisition of IT4KAN Sp. z o.o., a Katowice-based PACS software company founded in 2014 with a significant installed base in Poland; the purchase price was not disclosed but was stated not to exceed 5% of group equity (Inwestycje.pl). In the first half of FY2025/26 IT solutions sales rose 125% year on year, helped by that acquisition and by KPO-funded hospital digitisation projects (investor chat, 12 June 2026).

The core capability. What this segment knows how to do, that a new entrant does not, is convert a foreign manufacturer's product into a live, serviced, reimbursed installation inside a Central European public hospital, and then keep it running. The service organisation is the asset. It is also what makes the second and third sale in a country cheaper than the first.

Why it exists as one segment. Because the customer, the tender process, the field engineers and the sales organisation are shared. A hospital that bought a da Vinci from Synektik is the same buyer that will consider an APOTECA pharmacy robot or an ArPACS upgrade, approached by the same team through the same procurement channel. Management has been explicit that this cross-sell is intentional: non-da Vinci products accounted for 55% of equipment segment sales in H1 FY2025/26 (investor chat, 12 June 2026).

Competitive position. For da Vinci, Symani, ZAP-X, Exablate and Edison in its territories, Synektik has no competitor at all, because it holds exclusivity. The competition is at the platform level: a hospital choosing between da Vinci and Medtronic's Hugo, or CMR Surgical's Versius. For imaging and general equipment, the competition is intense and includes the manufacturers themselves selling direct.

How it fits into the group. This is the whole company. It is simultaneously the growth engine, the margin engine and the cash generator. Segment EBITDA over the first nine months of FY2025/26 was PLN 197.1 million, up 57% year on year, on revenue of PLN 692.5 million.

2.2 Radiopharmaceuticals

Share of revenue: PLN 40.9 million of PLN 733.4 million over the first nine months of FY2025/26, or roughly 6%.

What it does. Through Synektik Pharma, the group manufactures radioactive tracers used in PET-CT and SPECT diagnostics and sells them to imaging centres and hospitals. Products include Fludeoxyglucose (18F) and Glunektik, both FDG-type tracers used across oncology, cardiology and neurology; FLT (18F) for tumours with high mitotic activity; Fluorocholine (18F) for bone metastases and hepatocellular carcinoma; IASOglio for tumours with elevated amino acid uptake; Natrii fluoridum (18F) for bone metabolic activity; NanoSPECT for bone marrow and inflammatory conditions; Ioflupane (123I) ROTOP for dopaminergic neuronal assessment; the GalliaPharm generator for Gallium-68; and the Yttriga radiolabelling precursor (Synektik radiopharmaceuticals).

Production. Three sites: the Świętokrzyskie Oncology Centre in Kielce, the Military Institute of Medicine in Warsaw, and a production plant in Mszczonów. Per an SII analysis of the company, the Mszczonów facility was acquired in early 2018 and the highest-demand Polish products were moved there, a transaction that absorbed the Polish operation of the Turkish producer Monrol (SII analysis).

The core capability. A GMP-licensed cyclotron and radiochemistry operation is an expensive, heavily regulated, physically immovable asset. Synektik was the first private operator in Poland to get one licensed for commercial production, in 2012. Iason Sp. z o.o., acquired in 2010, was described as the first commercial producer of radiopharmaceuticals in Poland for oncological diagnostics.

Why it exists as a separate segment. Completely different economics, regulation and customer. It is a regulated pharmaceutical manufacturer selling a perishable product to imaging centres, some of whom (notably the Voxel group) are also competing producers. It is not a tender-driven capital equipment business at all.

Competitive position. Synektik describes itself as the leader in Poland in PET-CT radiopharmaceutical production. Its principal commercial rival is Voxel, which operates a cyclotron it owns in Kraków and one it leases in Warsaw. The state research institute NCBJ POLATOM is also a producer. Because half-life dictates geography, competition is regional rather than national: cyclotrons producing PET tracers operate in Bydgoszcz, Gliwice, Kielce, Kraków, Łódź, Mszczonów, Ożarów Mazowiecki and Warsaw.

How it fits into the group. Management presents it as the stabiliser: a small, steady, decent-margin annuity that does not swing with tender timing. In Q2 FY2025/26 its EBITDA margin was around 33.8%, comfortably above the equipment segment's roughly 30.3%. But it is also the part that is not growing much. Q3 FY2025/26 revenue was PLN 13.4 million against PLN 14.8 million a year earlier, and nine-month segment EBITDA of PLN 12.3 million was held back by higher logistics costs.

2.3 Segment comparison

3. Products and business detail

3.1 The robotics catalogue

da Vinci (Intuitive Surgical). Multi-arm robotic platform for minimally invasive soft-tissue surgery. In Poland it is used in urology, gynaecology, general and colorectal surgery, cardiac surgery and laryngology. The commercial package Synektik sells includes the system itself, the vision cart and console, staff training, warranty and post-warranty service, and successive deliveries of EndoWrist-class instruments and accessories that are life-limited by design. The economics follow the installed base: at the end of calendar 2025 Synektik had 83 da Vinci units under its care in Poland and 121 across the region; by end-March 2026 the regional active base was 132. Procedures performed in the region over the trailing twelve months exceeded 32,300 at the FY2024/25 year-end, growing 52% year on year, and passed 10,000 in a single quarter during H1 FY2025/26.

Symani (Medical Microinstruments). A robotic system for micro- and super-microsurgery, operating on structures at the scale of small blood vessels, nerves and lymphatic vessels, which are at or below the limit of what unaided human hands can reliably manipulate. Synektik is the exclusive distributor in Poland, the Czech Republic, Slovakia, Lithuania, Latvia and Estonia. Management's stated ambition for this product is modest and specific: a few units a year (Q3 FY2025/26 commentary, August 2026).

ZAP-X (Zap Surgical Systems). A self-shielded robotic radiosurgery platform for intracranial targets. Because it is self-shielded, it can be installed without building a bunker, which changes the capital and planning burden for a hospital considering stereotactic radiosurgery.

Exablate Neuro (Insightec). MR-guided focused ultrasound for neurosurgery, used principally to treat essential tremor by creating a precise thermal lesion in the thalamus without any incision.

Edison (HistoSonics). The newest and potentially most important addition. Histotripsy uses focused ultrasound to mechanically break apart and liquefy tumour tissue, without incisions, without ionising radiation and without heat. Synektik signed exclusive distribution for Poland, the Czech Republic, Slovakia, Lithuania, Latvia and Estonia in early 2026, for a three-year term with automatic renewal for two further years (Biznes PAP, report 1/2026). The system received CE certification on 13 July 2026, authorising use across the EU for liver tumours, with clinical studies running for kidney and pancreatic indications. Synektik cites a technical success rate above 95% in clinical studies and estimates roughly 27,000 new cases of primary liver, kidney and pancreatic cancer annually across its distribution territories (Synektik, 13 July 2026). Synektik is responsible for sales, service, consumables distribution, training, regulatory affairs and marketing.

3.2 Hospital pharmacy automation

APOTECA robot family and BD Rowa systems automate drug preparation and dispensing inside hospital pharmacies. APOTECA chemo automates the compounding of cytotoxic chemotherapy drugs, which is both a dosing-accuracy problem and an occupational-exposure problem for pharmacy staff. Irmatic electronic pharmacy showcases handle dispensing. This is a separate sales motion with a separate budget holder, and is one of the areas management points to when describing growth that is not dependent on surgical robotics.

3.3 IT and software

ArPACS is the proprietary family for archiving and communicating diagnostic images. Zbadani.pl is a telemedicine platform for digital diagnostic workflows. SynDose monitors patient radiation dose. MedDream Viewer handles image processing and viewing. AI-supported X-ray analysis applications and the SenVision temperature monitoring system round out the catalogue. The IT4KAN acquisition in January 2025 added an established PACS vendor with its own installed base and maintenance contracts.

This business is being pulled hard by regulation and by EU money. The European Health Data Space (EHDS) imposes EHR certification and interoperability obligations by 2029; the EU AI Act creates dual MDR-and-AI-Act compliance requirements for diagnostic AI tools; and NIS2 classifies hospitals as critical infrastructure with the cybersecurity obligations that follow. Roughly PLN 4.4 billion of KPO money is allocated to Polish healthcare digitisation over 2025 to 2027 (Synektik CEE 2030 report, June 2026).

3.4 Radiopharmaceutical manufacturing

Three GMP sites, two of them co-located inside major hospitals (the Świętokrzyskie Oncology Centre in Kielce and the Military Institute of Medicine in Warsaw), and a standalone plant in Mszczonów. Co-location is not incidental: it collapses the transport time that the isotope's half-life makes so expensive. A cyclotron accelerates protons into a target to create the isotope; radiochemistry modules then synthesise and purify the tracer; quality control must be completed and the batch released, all inside a window measured in hours.

3.5 Services and testing

Synektik has operated a specialist acceptance-testing laboratory for radiological devices since 2004, accredited since 2006 as the first private laboratory of its kind in Poland. It also performs diagnostic imaging equipment repair and maintenance, including on equipment it did not originally sell. Both activities are small in revenue but strategically useful: they put Synektik engineers inside hospitals that are not yet customers.

3.6 Geographies and the group's legal structure

Source: About Synektik Group.

Operational timeline by market: Poland from 2001; radiopharmaceutical exports to the Czech Republic and Slovakia from 2015; da Vinci distribution in the Czech Republic and Slovakia from 2022; Lithuania and Latvia operational from 2025; Estonia from 2026; Ukraine building its local team and company through 2026, with system registration expected around September 2026 and first installations expected in FY2026/27.

International revenue passed 20% of group sales in the nine months to June 2026, against a stated management target of 30%.

3.7 Milestones that changed the business

• 2010: acquisition of IASON Sp. z o.o. and licensing of radiopharmaceutical production technology
• 2012: first privately operated cyclotron in Poland licensed for commercial radiopharmaceutical production
• 2014: move from NewConnect to the main GPW market; R&D Centre opened
• 2018: merger of Synektik Pharma and Iason; acquisition of the Mszczonów plant; exclusive da Vinci distribution in Poland
• 2022: da Vinci exclusivity extended to the Czech Republic and Slovakia
• 2024: da Vinci exclusivity extended to Lithuania, Latvia and Estonia
• January 2025: acquisition of IT4KAN
• February 2026: Intuitive agreement extended to end-2031 and expanded to Ukraine
• March 2026: court registration of the demerger; SYN2 cardiotracer R&D separated into Syn2bio S.A.
• July 2026: Edison histotripsy system receives CE certification
• July and September 2026: first da Vinci contracts in Lithuania (Kaunas) and Estonia (Tallinn)

3.8 The Syn2bio demerger

In March 2026 the registry court registered a demerger by separation. The R&D activity around SYN2, a cardiac PET tracer for myocardial perfusion diagnostics that Synektik had been developing since obtaining worldwide rights in 2013, was moved into a new company, Syn2bio S.A., which issued 8,529,129 shares, exactly matching Synektik's share count, and allotted them 1:1 to Synektik shareholders. Syn2bio debuted on the GPW main market on 15 April 2026 as the 400th company listed there, with a reference price of PLN 23.20 (GPW announcement).

Three consequences matter for understanding Synektik today. First, Synektik no longer carries the cardiotracer R&D cost, estimated at roughly PLN 20 to 30 million a year, which management has linked directly to higher dividend capacity. Second, Synektik's reported nine-month FY2025/26 net profit of PLN 386.4 million includes a PLN 261.3 million non-cash accounting gain on the demerger; the continuing-operations figure is PLN 138.0 million, and that is the number that describes the operating business. Third, the risk profile of the equity changed: an investor in Synektik today is buying a distribution and service business, not a biotech option.

4. Customers

Who buys

Overwhelmingly, public hospitals: university clinical hospitals, voivodeship (regional) specialist hospitals, oncology centres and military medical institutes, across Poland, the Czech Republic, Slovakia and now the Baltic states and Ukraine. Named Polish buyers disclosed through significant-contract filings include University Clinical Hospital No. 2 of the Medical University in Łódź, Wojewódzki Szpital Specjalistyczny in Lublin, University Clinical Hospital No. 2 PUM in Szczecin, Szpital Wojewódzki in Bielsko-Biała and the hospital in Włocławek. Abroad, the buyers so far are the Lithuanian University Hospital Clinic in Kaunas and a hospital in Tallinn.

A minority of demand comes from private hospital groups: the 2026 robotic surgery report records 14 private hospitals performing robotic procedures in Poland in 2025, three of them operating without an NFZ contract at all (Modern Healthcare Institute report via mzdrowie.pl).

For radiopharmaceuticals the customer is different: imaging centres and hospital nuclear medicine departments, some of which belong to groups that are also competing producers.

Who makes the decision, and on what

For a surgical robot, the process typically starts clinically. A head of urology or colorectal surgery, usually one who has trained abroad or at a Polish reference centre, builds the case that the hospital needs robotic capability to retain surgeons and win referrals. The hospital's management then has to find capital, which in practice means matching the purchase to a specific funding programme: KPO, the National Oncology Network, the Medical Fund, a regional budget, or EU structural funds. Only then does procurement run a tender.

The tender itself is usually specified around a platform. Synektik has said openly that in some KPO tenders it has faced no competition at all on robotic systems, because the specification describes a da Vinci-class system and Synektik is the only party that can supply one in Poland (Puls Biznesu via Synektik, 13 June 2025).

The criteria, in rough order of weight: clinical capability and the specialties it unlocks; total cost of ownership over the contract life, including instruments; service response time and uptime guarantees; training provision; and the reference base, meaning how many similar Polish hospitals already run it successfully.

Sales cycles are long and lumpy. The clinical champion's campaign can run a year or more; the funding window then opens abruptly and closes on a hard date; the tender takes months; installation and training take months more. This is why Synektik's quarterly revenue moves the way it does, with PLN 124.7 million in Q2 FY2024/25 and PLN 292.3 million in Q3 FY2025/26.

Why they choose Synektik

Because for the platforms that matter most there is no alternative supplier. Where a hospital has decided it wants a da Vinci, a Symani, a ZAP-X, an Exablate or an Edison, Synektik is the only legal route in its territories. Where the choice is still open at platform level, the arguments are the size of the Polish da Vinci reference base (over 100 systems by early 2026, across 79 hospitals), the depth of the local service organisation, and the fact that NFZ reimbursement pathways for robotic procedures were built around the procedures da Vinci performs.

Switching costs

These are unusually high, and they compound.

Instrument lock-in. Robotic instruments are proprietary and life-limited. A hospital that buys a da Vinci is committed to buying its consumables from Synektik for as long as it operates the system, which is a decade or more.

Surgeon training. A robotic surgeon's proficiency is platform-specific. Poland had roughly 450 surgeons performing robotic procedures in 2025, over 210 of them urologists. Retraining a department on a different console destroys accumulated case volume and, for a period, operating-room throughput.

Service contract duration. The Tallinn contract bundles nine years of service and ten years of consumables into the original award. Switching does not just mean buying a new robot; it means breaking a decade-long supply relationship that is already paid for in the tender.

Reimbursement pathway. With 98% of Polish robotic procedures funded by the NFZ and over 56% reimbursed through higher-value procedure codes, the financial model of a robotic programme is built on existing coding practice.

The practical result is that the switching decision effectively happens once, at initial platform selection, and then not again for ten years or more.

Concentration

There is essentially no single-customer concentration. Synektik sells individual systems to dozens of separate hospital legal entities across seven countries. What it has instead is funding-source concentration and supplier concentration. A very large share of near-term demand traces back to one policy instrument, the KPO, and the great majority of segment revenue traces back to one manufacturer relationship, Intuitive Surgical. Those are the real concentration risks and they are dealt with in Section 8.

Contract structures and revenue predictability

Three layers, with different characteristics:

1. Capital equipment sales, won by tender, recognised largely on installation. Lumpy, highly visible in advance through the backlog, and the source of quarterly volatility. Contracts won in H1 FY2025/26 totalled PLN 311 million, more than double the prior-year period.
2. Recurring consumables and service, contracted for three to ten years alongside the equipment sale. PLN 291 million over nine months of FY2025/26, up 28%, and running near PLN 400 million on a trailing twelve-month basis. This is the annuity layer and management's stated target is for it to reach 60% of group revenue within two to three years.
3. Radiopharmaceutical supply, effectively a delivery subscription to imaging centres, priced per dose.

Visibility is reasonable at the one-to-two-quarter horizon: the company discloses a combined backlog and active offers figure each quarter. It stood at PLN 275 million entering FY2025/26, PLN 239 million after Q1, around PLN 280 million after H1, and above PLN 200 million after Q3.

5. Competitive landscape

The structure of the market

Synektik competes in three different games at once, and its position is very different in each.

Game one: platform selection inside the hospital. Here Synektik is not really the competitor; Intuitive Surgical is. When a Polish hospital decides which robotic surgery system to buy, it is choosing between da Vinci, Medtronic's Hugo RAS, CMR Surgical's Versius and Edge Medical's MP1000. Synektik wins or loses by proxy. The scoreboard as of early 2026 is lopsided: da Vinci in 79 hospitals with over 100 installations, against four Hugo RAS units in Poland (Jastrzębie-Zdrój, Bolesławiec, Kraków and Łomża) and one Versius at the Robotics Surgery Competence Center in Zabrze, installed October 2025 through a collaboration involving the Silesian University of Technology, Innovaris, Anmar Group and CMR Surgical. In orthopaedic robotics, a separate market Synektik does not serve, Smith+Nephew's Cori led with 11 installations across 26 hospitals performing robotic orthopaedic procedures.

Game two: imaging and general medical equipment distribution. Here Synektik is one of many. Siemens Healthineers, GE HealthCare, Philips and Canon Medical largely sell direct into Poland; Synektik competes both as a distributor of some of their products and as a bidder against them. Polish specialist distributors such as Consultronix (ophthalmology) occupy adjacent niches. Margins here are thinner and the competition is genuine.

Game three: radiopharmaceutical supply. A regional rather than national market, defined by isotope half-life. Synektik's main listed competitor is Voxel; NCBJ POLATOM is the state producer; Monrol, Curium and Novartis's Advanced Accelerator Applications are international players with varying Polish presence.

Named competitors

Market capitalisations above are peer-size references only, drawn from the dates stated; they are not applied to Synektik and no multiple is derived from them.

Where Synektik wins

Exclusivity plus execution. Exclusive rights are necessary but not sufficient; the reason Intuitive extended to 2031 and handed over Ukraine in the same amendment is presumably that Synektik has delivered. Poland went from a handful of robotic procedures a few years ago to 24,585 in calendar 2025, and Synektik's platform did most of them.

The installed-base flywheel. Every system sold enlarges the service and instrument annuity, which funds a deeper field organisation, which makes the next tender easier to win and the next hospital more confident. Regional active systems grew from 122 to 132 in a single quarter.

Cross-selling into a captive relationship. Non-da Vinci products were 55% of equipment sales in H1 FY2025/26. Synektik is using the robotics relationship as an entry point for pharmacy automation, IT and other therapeutic platforms.

Radiopharmaceutical geography. Half-life is a moat that cannot be attacked by capital alone, only by building a cyclotron in the same catchment.

Where Synektik is exposed

It does not own the technology. Every one of its high-margin robotics products is somebody else's. Synektik owns the channel, not the invention. Channels can be bought, and Intuitive has started buying them (Section 8).

It is a price-taker in imaging. In the general equipment business there is no moat, only tender pricing.

Platform competition is arriving, slowly. Hugo, Versius and the Chinese MP1000 are all present in Poland now. None has scale yet, but all three are cheaper than da Vinci, and public tenders are designed to be price-sensitive.

Barriers to entry

Genuinely high for a new distributor entering this specific niche, for the reason that there is nothing to enter: the rights are taken and run to 2031. Genuinely high for a new radiopharmaceutical producer, because of GMP licensing, capital cost and the fact that catchments are already served. Moderate for general equipment distribution, where the barrier is working capital and tender experience rather than anything structural.

The binding constraint on Synektik is not that someone else enters. It is that its own supplier decides to occupy the position itself.

6. Industry

What drives demand

Demand is driven by three things in sequence: clinical need, money, and rules.

Clinical need is structurally under-served. Poland performed roughly 341,500 procedures in 2025 in categories that could be done robotically, of which about 21,300 actually were, giving a penetration of about 6%. In general surgery specifically the figure is 2%, against 15% in the United States. Central and Eastern Europe as a whole is described in Synektik's own commissioned research as five to ten years behind Western Europe on robotic surgery penetration, AI adoption and pharmacy automation (Synektik CEE 2030 report, June 2026).

On the diagnostic side, Poland has roughly 0.7 PET-CT scanners per million population, a low figure for a country of its size and income, which caps radiopharmaceutical volume.

Money arrives in programmes, not in budgets. Almost PLN 18 billion of the Polish National Recovery Plan (KPO) is allocated to healthcare, covering hospital support, medical universities, digitisation and research. Within that: about PLN 4 billion for the digital transformation of more than 370 hospitals in the PSZ network, averaging around PLN 8 million each; PLN 5.2 billion for the National Oncology Network; PLN 2.7 billion for the National Cardiology Network; and PLN 1.5 billion for long-term care and geriatrics in county hospitals (Ministry of Funds and Regional Policy). Crucially, KPO carries a hard settlement deadline of 30 June 2026, extendable by contract amendment only to 31 August 2026. That deadline is the single most important fact about the FY2025/26 revenue shape.

Rules force modernisation independently of clinical enthusiasm. EHDS requires EHR certification and interoperability by 2029. The EU AI Act imposes dual MDR and AI Act compliance on diagnostic AI. NIS2 classifies hospitals as critical infrastructure with attendant cybersecurity obligations. These create demand for exactly the IT products Synektik has been assembling.

Market size and trajectory

Polish robotic surgery, calendar 2025: 24,585 procedures across 93 hospitals, up 44% from 17,100 procedures across 77 hospitals in 2024, which in turn was up 70% from 2023 (58 hospitals). Growth is decelerating from a very high base: 109% in 2023, 70% in 2024, 44% in 2025.

By specialty in 2025: urology 61% (15,032 procedures, of which 13,231 were radical prostatectomies, representing 82% of all prostate cancer surgery in Poland); colorectal 17% (4,181 cases, up 81%); gynaecology 12% (2,992 cases); thoracic, cardiac, head and neck and paediatric together about 6%. One centre, the Bydgoszcz Oncology Centre, passed 1,000 robotic procedures in a single year, a Polish first.

Workforce: roughly 450 surgeons performed robotic procedures in 2025, including about 40 women. This is a real constraint on volume growth, and it is also why training provision is a competitive weapon.

Forward market growth rates cited in Synektik's 2030 report: surgical robotics at a 14.8% CAGR; diagnostic AI growing from USD 1.6 billion to USD 5.44 billion (22.46% CAGR); healthcare cloud from USD 54.69 billion to USD 93.41 billion (11.3% CAGR).

Where Synektik sits in the supply chain

Squarely in the middle. Upstream sit the technology owners (Intuitive, HistoSonics, MMI, Insightec, Zap Surgical, BD, Hologic, Philips). Downstream sit public hospitals and, behind them, the NFZ as payer and the EU and Polish state as capital providers. Synektik converts a product into an installed, trained, serviced, reimbursed clinical capability. In radiopharmaceuticals it is further upstream: it is the manufacturer.

Import substitution

The equipment business is pure import: none of the robotics platforms is made in Poland or anywhere near it, and Synektik's role is precisely to import them. Radiopharmaceuticals are the opposite, and by physical necessity. Before 2012 Poland had essentially no commercial domestic PET tracer production; Synektik installed the first privately operated licensed cyclotron that year and Voxel followed in 2013. Poland's national audit office has noted that radiopharmaceuticals from private entities proved cheaper and more accessible (NIK via Medycyna Prywatna). This is a completed substitution, not an ongoing one.

Regulation

Medical devices require CE marking under the EU Medical Device Regulation, and national registration in each market (Ukraine is outside the EU and requires its own registration, expected around September 2026 for da Vinci). Radiopharmaceuticals are medicinal products requiring GMP manufacturing authorisation and marketing authorisation per product. Radiological equipment requires periodic acceptance and consistency testing, which Synektik's accredited laboratory performs. Reimbursement is set by the NFZ, and the creation of higher-value procedure codes for robotic prostatectomy, colorectal and endometriosis surgery is what made the Polish robotic market economically viable for hospitals.

Cyclicality

This is not an economically cyclical industry so much as a policy-cyclical one. Demand does not track GDP; it tracks the opening and closing of funding programmes. Oncology incidence is essentially acyclical, and the NFZ pays regardless of the business cycle, so the recurring layer is genuinely defensive. The capital equipment layer, by contrast, is governed by EU budget cycles, which means it can produce a year of exceptional orders followed by a year of drought.

Tailwinds and headwinds

Tailwinds: a penetration gap of 6% versus 15%; a decade of catch-up against Western Europe; roughly PLN 18 billion of KPO healthcare money in flight; regulation (EHDS, AI Act, NIS2) that forces IT spend regardless of enthusiasm; ageing populations raising cancer incidence; and a surgeon population being trained on robotic platforms whose careers will run for decades.

Headwinds: the KPO cliff in mid-2026 with no confirmed successor programme of equal size; chronic NFZ budget pressure; a shortage of trained robotic surgeons capping procedure growth; and cheaper competing platforms entering price-sensitive public tenders.

7. Growth triggers

Extracted from the six reporting periods listed in Section 9, plus the 12 June 2026 investor chat. Each is attributed to the specific management statement and date.

• Ukraine market entry, with roughly 20 da Vinci installations planned over two years. The Intuitive agreement was amended in February 2026 to add Ukraine and extend all territories to the end of 2031. Synektik has been building a local team and company entity through 2026; system registration in Ukraine was expected around September 2026, with first sales landing in FY2026/27. (Q1 FY2025/26 commentary, 13 February 2026; reiterated in the H1 briefing, 11 June 2026, and the investor chat, 12 June 2026, and again at Q3, 6 August 2026 - repeated across four consecutive periods.)

  "First installations in Ukraine are expected in the next financial year starting in October."

  • Dariusz Korecki, Vice President (Parkiet interview, 24 June 2026)

• Baltic revenue arriving now. First da Vinci contract in Lithuania signed with the Lithuanian University Hospital Clinic in Kaunas in July 2026; first Estonian contract signed 17 September 2026 with a Tallinn hospital at EUR 9.4 million net, including nine years of service and ten years of consumables. (Q3 FY2025/26 commentary, 6 August 2026, for Kaunas; company release, 17 September 2026, for Tallinn.)

• Edison histotripsy commercialisation. CE certification obtained 13 July 2026 for liver tumours, opening EU sales across Synektik's six Edison territories, with kidney and pancreatic indications in clinical study. Management stated that the first months of sales will establish the forecast. (Q3 FY2025/26 commentary, 6 August 2026; certification announced 13 July 2026.)

  "We expect the first users to be the most innovative medical centres, while adoption pace will depend primarily on reimbursement processes and clinical experience accumulation."

  • Dariusz Korecki (Synektik, 13 July 2026)

• da Vinci unit target raised twice within one fiscal year. From "closer to low 30s" to "closer to high 30s" at the H1 briefing, with 28 units already sold by the Q3 report and a confirmed target above 30 for FY2025/26. (Guidance raised 11 June 2026; confirmed 6 August 2026.)

  "We're counting on about 30-some units this year. A few quarters ago we said closer to low 30s, today we say closer to high 30s."

  • Dariusz Korecki (StockWatch, 11 June 2026)

• Recurring revenue path to 60% of group sales. Management targets recurring revenue reaching 60% of total within two to three years, from 51% in FY2024/25, and states it can sustain growth above 25% a year in that line. (Stated at Q1, 13 February 2026, restated at the investor chat, 12 June 2026, and in the Parkiet interview, 24 June 2026 - repeated across three periods.)

  "We can maintain dynamics of over 25% long-term."

  • Dariusz Korecki on recurring revenue (Parkiet, 24 June 2026)

• IT segment scaling on KPO digitisation money. IT solutions sales rose 125% in H1 FY2025/26, attributed to the IT4KAN acquisition and KPO-funded hospital projects. (Investor chat, 12 June 2026.)

• Symani microsurgery rollout. Management targets several units a year from the Symani platform. (Q3 FY2025/26 commentary, 6 August 2026.)

• Acquisitions under active consideration. Management stated it is looking at companies with proprietary products in radiopharmacy or IT that operate within its existing customer base, and is "not excluding" acquisitions. (Parkiet interview, 24 June 2026; reiterated by Korecki at Q3, 6 August 2026, framed as organisational and financial capacity for both organic growth and M&A.)

• Target of 30% of group revenue from foreign markets. International sales passed 20% in the nine months to June 2026. (Q3 FY2025/26 commentary, 6 August 2026.)

Trigger summary

8. Key risks

8.1 Intuitive Surgical taking European distribution in-house

This is the defining risk, and it is not hypothetical.

The mechanism: Synektik's dominant business is a distribution agreement it does not control. Intuitive can, at renewal or by negotiated buyout, decide that a market has grown large enough to serve directly. When it does, the distributor's economics change overnight: it loses both the capital sale and the far more valuable instrument and service annuity attached to the installed base it built.

Why this is elevated rather than theoretical: on 2 March 2026, Intuitive completed the acquisition of the da Vinci and Ion distribution businesses of ab medica, Abex and Excelencia Robótica for approximately EUR 319 million upfront, taking Italy, Spain, Portugal, Malta and San Marino direct and absorbing roughly 250 distributor employees (MedTech Dive, 2 March 2026). Intuitive has stated it will operate directly in the majority of Europe. Those three markets had over 470 da Vinci systems installed at end-2025.

Poland is a fraction of that size today, which is precisely the argument for why Synektik is safe for now and precisely the argument for why it becomes less safe as it succeeds. The installed base has gone from 83 systems in Poland at end-2025 to over 100 by early 2026, with a regional base of 132 by March 2026 and management describing Poland as only "halfway through saturation."

Calibration: moderate probability over the life of the current agreement, very high impact. The mitigants are real but partial: the agreement runs to the end of 2031, Intuitive extended and expanded it one month before the Italian buyout rather than after, and a buyout would presumably be compensated. But compensation for an annuity is a one-time payment, and the business that remains afterwards is a much smaller imaging, IT, pharmacy-automation and radiopharmaceutical company.

8.2 The KPO funding cliff

The mechanism: a large share of FY2025/26 demand was pulled forward by the KPO settlement deadline of 30 June 2026 (extendable to 31 August 2026). Hospitals had to place and settle orders before that date or lose the grant. Q3 FY2025/26 equipment sales of PLN 175.3 million were roughly three times the prior year. If there is no successor programme of comparable size, FY2026/27 equipment revenue faces an air pocket.

Management has acknowledged the deceleration directly:

"Dynamics will certainly decrease in the coming months, but this doesn't mean we've peaked."

• Dariusz Korecki (StockWatch, on the Q3 FY2025/26 results, August 2026)

At the investor chat on 12 June 2026, management said KPO procurement deadlines were "manageable" with no threats to FY2026 project delivery. That is a statement about delivering what has been won, not about what replaces it.

Calibration: high probability of a visible order slowdown, moderate impact. The recurring layer (approaching PLN 400 million annualised) is not affected by the cliff and grows with the installed base regardless. The National Oncology Network allocation of PLN 5.2 billion and the National Cardiology Network's PLN 2.7 billion are partial successors. But a business that grew 89% in a quarter will be comparing against that quarter a year later.

8.3 Working capital and cash conversion

The mechanism: Synektik buys equipment in EUR or USD from manufacturers and sells to public hospitals in local currency on public-sector payment terms. When equipment sales spike, so does the working capital absorbed. In Q2 FY2025/26 the group reported operating cash flow of minus PLN 19.0 million despite strong reported profit, with receivable days rising from 56.4 to 76.4 (SII analysis).

The balance sheet absorbs this today: net debt was below 0.1x trailing EBITDA at H1 FY2025/26, and at Q3 Korecki stated the cash surplus exceeded interest-bearing obligations by roughly PLN 36 million, after paying out about PLN 92 million in dividends in the half. But the company is simultaneously paying out nearly all of its standalone profit as dividends and funding an accelerating equipment business, and those two demands compete.

Calibration: high probability of continued lumpy cash conversion, low-to-moderate impact given current gearing.

8.4 Concentration in one procedure

The mechanism: 61% of Polish robotic procedures in 2025 were urological, and 13,231 of those were radical prostatectomies, representing 82% of all Polish prostate cancer surgery. Prostatectomy is close to saturated as a robotic indication in Poland. Future procedure growth, which drives the instrument annuity, has to come from colorectal (17% and growing 81%), gynaecology (12%) and general surgery (2% penetration). If those specialties adopt more slowly than urology did, consumables growth decelerates even with a growing installed fleet.

Calibration: high probability, moderate drag rather than a break.

8.5 Competing platforms compressing tender pricing

The mechanism: Hugo RAS (four Polish units by January 2026), Versius (one, from October 2025) and Edge Medical's MP1000 are all now present. In a public tender, price carries explicit weight. A hospital that would previously have written a specification only da Vinci could meet may increasingly write one that three platforms can meet, which turns a no-competition tender into a price auction.

Calibration: moderate probability over three to five years, moderate impact. Synektik has said that in some KPO tenders it faced no competition on robotics; that is a description of the present, not a guarantee.

8.6 Ukraine operational and country risk

The mechanism: Synektik has built a local subsidiary, is planning roughly 20 installations over two years, and expects first revenue in FY2026/27. Ukraine is an active conflict zone with unresolved reconstruction financing. Hospital capital budgets, device registration timelines, payment reliability and physical security of installed equipment are all uncertain. Management excluded Ukraine from FY2026 targets, which is appropriately conservative, but the growth narrative increasingly leans on it.

Calibration: moderate-to-high probability of delay, moderate impact (it is upside that may not arrive, rather than existing profit at risk).

8.7 Radiopharmaceutical margin erosion

The mechanism: the segment's revenue fell year on year in Q3 FY2025/26 (PLN 13.4 million against PLN 14.8 million) and nine-month EBITDA was held back by higher logistics costs. Logistics are structurally expensive in a business where the product decays in transit, and the cost is not easily passed on to hospitals buying at tendered prices. Poland's low PET-CT density (0.7 scanners per million) caps the addressable volume.

Calibration: high probability of continued low growth, low impact given the segment is only 6% of revenue.

8.8 Key-person concentration

The mechanism: Cezary Kozanecki founded the company in 2001, has been President of the Management Board throughout, and remains the largest shareholder at 16.8%. The supplier relationships that define the business, particularly with Intuitive, were built under his tenure. His August 2026 sale of 7.2% of the company reduced but did not eliminate his alignment.

Calibration: low probability, high impact.

8.9 Reimbursement policy

The mechanism: 98% of Polish robotic procedures are NFZ-funded and over 56% attract higher-value procedure codes. A decision to narrow those codes or reduce the differential would immediately damage hospital economics for robotic programmes and slow new installations. Management argued at the 12 June 2026 investor chat that NFZ budget pressure poses "no essential impact" because of alternative funding sources (the Medical Fund, regional budgets, private payment) and revenue diversification. That is a reasonable argument about capital purchases; it is a weaker argument about procedure volumes, which drive the consumables annuity.

Calibration: low-to-moderate probability, high impact if it occurs.

9. Walk the talk

The six reporting periods used

1. Q2 / H1 FY2024/25 (Jan-Mar 2025 quarter; half-year Oct 2024-Mar 2025), report and management briefing 13 June 2025
2. Q3 FY2024/25 (Apr-Jun 2025), report and briefing 19 August 2025
3. Q4 / FY2024/25 (Jul-Sep 2025 quarter; full year), Q4 report and briefing 18 November 2025; annual report 19 December 2025
4. Q1 FY2025/26 (Oct-Dec 2025), report and briefing 12-13 February 2026
5. Q2 / H1 FY2025/26 (Jan-Mar 2026 quarter; half-year Oct 2025-Mar 2026), report and briefing 11 June 2026; investor chat 12 June 2026
6. Q3 FY2025/26 (Apr-Jun 2026), report and briefing 5-6 August 2026

The most recent is 51 days before this report's date, comfortably inside 90 days.

The record

Starting point, June 2025. At the half-year mark of FY2024/25, Synektik reported revenue of PLN 327.8 million with EBITDA of PLN 80.9 million, up only 4% year on year, but with recurring revenue up 64% to PLN 145.5 million and a backlog above PLN 220 million. The message from Dariusz Korecki was that the recurring layer was doing the structural work while the equipment cycle was in a lull, and that KPO tenders were about to turn.

"Recurring revenues provide stability and predictability of results." He added that KPO-financed tenders were launching, describing it as "just the beginning" with expectations for "rapid sales growth."

• Dariusz Korecki (Puls Biznesu, 13 June 2025)

He also said the company was submitting six bids worth over PLN 10 million in a single week, three of them for robotic systems where it faced no competition. That is an unusually checkable claim. What happened next: equipment revenue went from PLN 124.7 million in Q2 FY2024/25 to PLN 292.3 million total revenue in Q3 FY2025/26 four quarters later, with equipment sales tripling in that quarter alone. The "wave of tenders" call was correct and was made a full year before the wave crested.

August 2025. At Q3 FY2024/25, Korecki committed to a specific full-year outcome:

"Results for the full 12-month period will certainly be significantly better than the previous year."

• Dariusz Korecki (StockWatch, 19 August 2025)

He also said the company maintained plans to sell one to two da Vinci robots in the Baltic states during calendar 2025.

Outcome on the first promise: delivered. FY2024/25 closed with revenue of PLN 681.3 million against PLN 624.1 million, EBITDA of PLN 177.1 million against PLN 143.1 million (up 24%), and continuing-operations net profit of PLN 125.2 million against PLN 98.5 million. "Significantly better" is a fair description of a 24% EBITDA increase.

Outcome on the second promise: missed, and quietly. The first Baltic da Vinci contract was signed with the Lithuanian University Hospital Clinic in Kaunas in July 2026, roughly eighteen months after the calendar-2025 target. The Estonian contract followed in September 2026. Synektik did begin operations in Lithuania and Latvia in 2025 and Estonia in 2026, so the market-entry half happened; the sales half slipped by a year and a half. Notably, this slippage was not called out at the time. By the 12 June 2026 investor chat the Baltics were described in forward terms again ("several pipeline projects" and "expected installations this fiscal year") rather than as a missed 2025 target.

November 2025. Q4 FY2024/25 delivered the company's record quarter to that point: revenue PLN 199.2 million, EBITDA PLN 54.6 million, net profit up 72%. Management disclosed 27 da Vinci systems sold and installed in the year, 9 of them in Q4, and entered the new year with a record PLN 275 million of backlog plus active offers. The Syn2bio demerger prospectus had been filed with the regulator in November.

February 2026. Q1 FY2025/26 was the weakest optical quarter of the six: revenue up only 12% to PLN 228.0 million, EBITDA up 18%. Korecki made a specific and falsifiable forecast:

The company expects "dynamics of our results to improve from current dozen-plus percent to clearly above 20 percent."

• Dariusz Korecki (Parkiet, 17 February 2026)

He also guided to recurring revenue reaching about 50% of sales for the fiscal year and 60% within two years, and said Syn2bio's separation was planned for April with a GPW debut around then.

Outcome: over-delivered on all three. Revenue growth went from 12% in Q1 to 71% in Q2 to 89% in Q3, far beyond "clearly above 20 percent." Syn2bio was registered by the court on 27 March 2026 and debuted on the GPW on 15 April 2026, precisely on the stated schedule. Recurring revenue reached PLN 291 million over nine months, up 28%.

June 2026. At the half-year, management made two forward commitments. The first was on second-half performance:

"The second half of this fiscal year will be at least as good as the first half, and I assume it will even be better."

• Dariusz Korecki (Parkiet, 24 June 2026)

The second was the raised da Vinci target, from "closer to low 30s" to "closer to high 30s," which at the 12 June investor chat was stated as "35+ units being realistic."

Outcome on H2: delivered on the first leg. Q3 revenue of PLN 292.3 million alone exceeded either quarter of H1, and Q3 EBITDA of PLN 71.5 million exceeded both.

Outcome on the unit target: partially walked back. By the Q3 report on 6 August 2026, 28 units had been sold and management confirmed a target of "30+." "30+" is a materially weaker statement than "35+ realistic" made eight weeks earlier. That is a soft downgrade inside a single fiscal year, delivered without being flagged as one, and it is the second instance of the same pattern seen with the Baltic robots: an enthusiastic unit-count guide that is later restated downward in passing.

August 2026. Q3 was the strongest quarter in the company's history: revenue PLN 292.3 million (up 89%), EBITDA PLN 71.5 million (up 72%), continuing net profit PLN 55.1 million. Kozanecki noted that nine-month results exceeded the prior full year's records, and that international sales had passed 20% of the group against a 30% target. Korecki set expectations down for the period ahead in plain terms, saying dynamics would decrease while denying a peak.

Promise versus outcome

Assessment

This is management that delivers on financial outcomes and is loose on unit counts.

On every statement about revenue, profit, cash and corporate actions across the six periods, the outcome was at or above the guide, and in the February 2026 case dramatically above it. The Syn2bio demerger was executed to the month. Recurring revenue has tracked the stated path. The single most important strategic call, that the KPO tender wave was coming, was made in June 2025 and was right.

Against that, two specific unit-count guides were set optimistically and then quietly revised: the Baltic robots promised for calendar 2025 that arrived in mid-2026, and the "35+ realistic" da Vinci figure softened to "30+" within eight weeks. Neither was announced as a change; both were absorbed into forward-looking language in a later briefing. A careful reader has to track them across periods to see the revision, which is exactly the shape of communication that rewards close attention and punishes casual reading.

The fair summary: they do what they say on the numbers that hit the income statement, and they are consistently a quarter or two early on the unit and geography milestones they get excited about. Management is more accurate about how much money the business will make than about when a specific robot will be sold in a specific country. For a business whose reported results have beaten consensus on profitability in the periods where a consensus existed, that is a good failure mode to have, but it means forward-looking unit targets should be discounted by roughly one to two quarters as a matter of habit.

10. Shareholder friendliness index

Dividends. Synektik has paid a dividend from the profits of each of the last three completed financial years, and the per-share amount has risen steeply each time: PLN 3.03 from FY2021/22 (approved 26 February 2024), PLN 8.25 from FY2022/23 (approved 22 January 2025), and PLN 10.75 from FY2023/24, which was approved by the AGM on 20 January 2026 with a record date of 29 January and payment on 2 February 2026 (Synektik stock and shareholders page; Biznes PAP). The trend is unambiguous growth, more than 30% year on year in the most recent step. The payout ratio is the one number that adds information here: the latest distribution of PLN 91.69 million represented 99.7% of the PLN 91.94 million standalone net profit of the parent company for the year ended 30 September 2025. That is effectively a full payout, made possible because the group's capital needs are working capital rather than fixed assets. Management has signalled continuity, with Korecki saying in June 2026 "we will recommend paying a high dividend," and has linked the Syn2bio demerger, which removed roughly PLN 20 to 30 million a year of cardiotracer R&D spend, to higher dividend capacity. The company states it has no formal dividend policy and decides case by case. Note that the company paid no dividend at all between 2011 and 2018.

Buybacks and dilution. No share buyback programme was announced or executed in the last three financial years. MoatMap's disclosure feed records zero buyback transactions in the trailing ~90 days (since 27 June 2026), and separate searches of Warsaw Stock Exchange announcements, financial press coverage and the company's own investor pages found no buyback programme authorisation at any point across the three years to September 2026; the company's shareholder page discloses no treasury shares. Shares outstanding stand at 8,529,129 and the dividend arithmetic corroborates that this count has been stable (the PLN 91.69 million distribution at PLN 10.75 per share implies 8.53 million shares). There is no option-driven dilution visible. Separately, shareholders received value in kind rather than cash through the March 2026 demerger: every Synektik share carried an entitlement to one Syn2bio share, with Syn2bio issuing exactly 8,529,129 shares to match, so the cardiotracer asset was handed directly to owners rather than sold or retained.

Verdict: Returns Capital. A near-100% payout of standalone earnings, a dividend that has roughly tripled in three years, and a demerger that distributed a development asset to shareholders in specie rather than retaining it, with no offsetting dilution.

11. Insider activities

Source note. Poland's insider disclosure regime runs through KNF and the ESPI/EBI announcement system, whose portals are gated and return blocked or empty stubs to automated retrieval. Per the instruction accompanying this report, the MoatMap cross-market disclosure database is treated as the canonical source for MAR Article 19 insider dealing on this venue, and its feed for SNT.WA is reproduced below in full. Data current as of 25 September 2026, 12:57 UTC.

One material transaction that is publicly reported in the Polish financial press but does not appear in the MoatMap feed is included separately below and clearly labelled, because omitting it would materially misrepresent the last 12 months.

Recent transactions

MoatMap feed aggregate for the trailing 12 months: 2 buys, 1 sell, 0 other, across 3 distinct insiders.

Buys: reading the signal

There are two open-market purchases in the window, both by persons closely associated with Sawa Zarębińska, a member of the Supervisory Board, and both executed within two days of each other in late March 2026 at PLN 262.40 and PLN 271.00 per share (MoatMap insider feed, 2026-03-23 and 2026-03-25).

These are not a meaningful conviction signal, and it would be misleading to dress them up as one. Maciej Zarębiński bought 382 shares for approximately PLN 100,000 and Zuzanna Zarębińska bought 55 shares for approximately PLN 15,000. Combined, that is around PLN 115,000, or 0.00% of shares outstanding. The timing is interesting only in that both fall in the week the demerger was registered by the court (27 March 2026), which is consistent with routine post-event portfolio housekeeping by family members of a board member rather than a directional call on the business. Two related parties buying in the same week is technically a cluster, but a cluster this small in a company of this size carries no information content.

There were no open-market purchases by the President, the Vice President, or any member of the Management Board in the trailing 12 months.

Sells: working out the why

Książek Holding, 17 June 2026, 1,376,143 shares at PLN 300.00, PLN 412.8 million, 16.13% of the company. This was a complete exit, executed as an accelerated bookbuild at a roughly 6% discount to the previous close, with settlement on 19 June 2026 (StockWatch; Parkiet). The reason is best understood from the investment's history rather than from any statement about the business: Książek Holding first invested in December 2017, acquiring a 26.1% stake and becoming the largest shareholder; it sold a 10% tranche in February 2025 at PLN 225 per share for approximately PLN 192 million; and it sold the remainder eighteen months later at PLN 300. That is the completion of a staged exit from a financial investment held for eight and a half years, at a very large gain, by a holding company whose business is not medical technology. No adverse reason was disclosed. The share price fell sharply on the announcement, which is the normal mechanical consequence of a 16% block clearing at a discount.

Melhus Company Ltd (Cezary Kozanecki), 22 August 2026, 615,000 shares at PLN 350.00, PLN 215.25 million, 7.2% of the company. This transaction is publicly reported but does not appear in the MoatMap feed, so it is flagged here as an addition from public reporting rather than from the canonical disclosure feed. The founder and President sold 7.2% of the company through his holding vehicle, reducing his stake from approximately 24% to 16.8%, at which level he remains the largest shareholder (Strefa Inwestorów, 22 August 2026). The reason was disclosed as personal needs, with Kozanecki describing this as a moment to become "not only co-author, but also, in part, beneficiary" of the company's success, noting the stock's appreciation of more than 1,500% since listing. He stated explicitly:

"My goal is the further implementation of strategy and dynamic growth of the Company's value. I do not plan to sell further shares."

This is founder diversification after a long and very large run, disclosed with a forward commitment not to sell more. It is not a scheduled plan (Poland has no 10b5-1 equivalent), not an estate distribution, and not tax-driven vesting. It is a discretionary decision, and it followed a comparable exit by the other large holder two months earlier.

Net assessment

Insiders were overwhelmingly net sellers over the last 12 months: approximately PLN 628 million of disposals against approximately PLN 115,000 of purchases. The selling is concentrated in exactly two holders, and both sales were block trades rather than dribbled-out disposals.

The interpretation is genuinely mixed rather than simply negative. Both sellers are long-duration holders monetising an exceptional return: Książek Holding after eight and a half years, Kozanecki after twenty-five years of building the company. Neither sale coincided with a disappointing result; Książek sold six days after the half-year report showed revenue up 35% and net profit up 50%, and Kozanecki sold sixteen days after the strongest quarter in the company's history. Both were executed at prices well above where the previous tranche had cleared, and Kozanecki's PLN 350 was 17% above Książek's PLN 300 two months earlier. Kozanecki retains 16.8% and has publicly committed not to sell further.

Against that, there is a real change in the shareholder register. Within nine months the company went from having a 26%-then-16% financial anchor and a ~24% founder to having a founder at 16.8%, Nationale-Nederlanden pension funds at 8.97%, and roughly three quarters of the register in "other" hands. That is a much more diffuse ownership structure, and it removes the block that would most naturally have resisted, for instance, a buyout of the distribution business by its supplier.

There has also been no open-market buying by any executive or board member in the window, only two token purchases by relatives of a Supervisory Board member. A management team that genuinely believed the shares were mispriced after the Q3 results had an obvious way to say so, and did not use it.

Read: mild concern. Not a red flag, because both sales have clear non-fundamental explanations, were fully disclosed, were executed at rising prices, and left the founder as the largest holder with a stated commitment to stay. But two insiders taking more than PLN 600 million off the table within nine weeks of each other, with zero offsetting executive buying, is a pattern that deserves to be held in mind rather than explained away.

12. Scenarios

Bull case

The KPO cliff turns out to have been a speed bump rather than a wall. The National Oncology Network's PLN 5.2 billion and the National Cardiology Network's PLN 2.7 billion arrive in size through FY2026/27, and the next EU budget period produces a successor instrument before the current one fully drains. Polish hospitals keep buying robots because the clinical case is now self-evident, and because the surgeon cohort trained over the last three years demands the tools. Penetration moves from 6% toward 10%, driven not by more prostatectomies but by colorectal and general surgery, where the gap to the United States is widest. Every one of those additional procedures consumes instruments Synektik supplies exclusively.

The geographic story compounds on top. Ukraine registers da Vinci on schedule, reconstruction financing reaches hospital capital budgets, and the roughly 20 installations management has sketched over two years actually happen, opening a market with tens of millions of people and essentially no installed base. The Baltics, having produced their first two contracts in mid-2026, become a steady two or three systems a year with nine and ten year service tails attached to each. International revenue passes the 30% target and keeps going, and the group is no longer a bet on one country's EU funding cycle.

Meanwhile the newer platforms stop being options and start being businesses. Edison, CE-certified in July 2026, finds its first adopters in the innovative oncology centres management expects, and as kidney and pancreatic indications clear their studies it becomes a second annuity with its own consumables. Symani settles into several units a year. Hospital pharmacy automation and the IT4KAN-enlarged software business ride the EHDS, AI Act and NIS2 compliance wave through 2029 with a mandatory quality to the demand. Recurring revenue crosses 60% of sales as management has guided, the mix shifts decisively away from lumpy capital sales, and the business starts to look like a maintenance company with an equipment arm rather than the reverse. Intuitive, watching a partner execute across seven countries and having just signed to 2031, decides the region is better served as it is.

Base case

Synektik closes FY2025/26 having sold somewhere around 30 da Vinci systems, delivers on the "H2 at least as good as H1" commitment, and reports a record year on revenue, EBITDA and continuing net profit. Then the comparison problem arrives. FY2026/27 has to lap a year that was inflated by hospitals rushing to settle KPO grants before the June and August 2026 deadlines, and equipment revenue growth flattens or falls, exactly as Korecki signalled when he said dynamics would decrease.

What holds the year together is the annuity. The installed base, now well over 130 systems regionally and growing, throws off service and instrument revenue that does not care about tender cycles, and management's 25%-plus growth target for that line is broadly met. Recurring revenue climbs toward the 55 to 60% share that has been guided for two years. Group revenue growth slows to something more ordinary while margins hold, because the recurring mix is the higher-margin one.

Ukraine produces first installations but later and in smaller numbers than the 20-over-two-years sketch, consistent with management's established habit of being a quarter or two early on geography milestones. Edison sells a handful of systems to reference centres and is still waiting on reimbursement pathways rather than generating meaningful revenue. The Baltics add contracts at a steady but unspectacular pace. Radiopharmaceuticals continue to bump along at a few percent growth with logistics costs eating into margin.

The dividend stays large, because the demerger removed the R&D drain and there is nothing else to spend the standalone profit on. Management makes one or two small bolt-on acquisitions in radiopharmacy or medical IT, as it said it was considering. The Intuitive relationship runs on unchanged, and nobody has to think about 2031 yet.

Bear case

The KPO cliff is a real cliff. Polish hospitals spent their grant money by August 2026 and have nothing left; the successor programmes are slower and smaller than hoped, and the next EU budget period does not deliver at scale until 2028. Equipment revenue, which tripled in Q3 FY2025/26, falls by half against that comparison. The backlog, which has been disclosed each quarter and was above PLN 200 million at Q3, drains without being replenished, and the market discovers that a distribution business with no orders has very little operating leverage to work with.

Worse, the annuity does not fully compensate, because procedure growth decelerates too. Robotic prostatectomy is already 82% of Polish prostate cancer surgery, so there is almost nothing left to convert there; colorectal and gynaecology grow, but Poland has only about 450 robotic surgeons, and training capacity, not robot availability, becomes the binding constraint. Instrument revenue per installed system plateaus.

Then the structural risk arrives. Poland's installed base, having passed 100 systems and being described by management as only halfway to saturation, becomes large enough to be worth owning directly. Intuitive, which in March 2026 paid roughly EUR 319 million upfront to take Italy, Spain and Portugal in-house and absorb 250 distributor staff, does the arithmetic on Central Europe. Even a well-compensated buyout leaves Synektik as a much smaller company: an imaging and general equipment distributor competing on price against Siemens, GE and Philips, a pharmacy automation business, a software business, and a PLN 55 million a year radiopharmaceutical operation with flat revenue and rising logistics costs. The register, now that both the financial anchor and more than a third of the founder's stake have been sold, has no large holder positioned to argue for a different outcome.

In a milder version of the same story, Intuitive stays, but Hugo, Versius and the Chinese MP1000 accumulate enough Polish references that tender specifications stop being written around a single platform. Price becomes the deciding criterion in a public procurement system designed to make it so, the no-competition tenders Korecki described in 2025 disappear, and the margin on each capital sale compresses toward distribution economics. Ukraine, meanwhile, is delayed indefinitely by the war and the working capital tied up in a market that cannot pay reliably becomes a cost rather than an option.